Justlight, AdobeStockInverna Therapeutics, a Danish biotech company, has officially launched to develop innovative RNA-based therapies targeting severe genetic diseases. Co-founded by the University of Southern Denmark and Argobio, Inverna will focus on its lead programme addressing Huntington’s disease.
Jeyaratnam Caniceus/Pixabay.comVerdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.
XyloCor TherapeuticsA US$67.5m Series B financing in XyloCor Therapeutics led by French Jeito Capital will fund two double-blind Phase 2 trials for XC001, a pioneering gene therapy for severe cardiovascular disease.
123rf.com/valentinakruThe aim of this unique initiative, part of the so-called Generation Study, is to sequence the genomes of 100,000 newborns in England to enable the early detection of over 200 selected conditions and to accelerate the treatment of rare diseases.
IPS-Integrated Project Services, LLC / WuXi BiologicsWuXi Biologics has agreed to sell its Dundalk vaccine manufacturing facility to Merck, a move that will enhance asset efficiencies and allow the company to focus on CDMO services at its other global sites.
Orbis MedicinesOrbis Medicines secures €90m in Series A funding to accelerate the development of oral macrocycle drugs, leveraging automated chemistry and machine learning.
pixabay.com - geraltThank you for a successful 2024!
SK BioscienceIn parallel with the expansion of its collaboration with SK Bioscience Co. Ltd, the French pharmaceutical company Sanofi SA has announced Phase III testing of its licensed pneumococcal conjugate vaccine PCV21.
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015Screening a library of 712 market-approved drugs, German researchers have found that a cough medicine most efficiently reduced incurable lung fibrosis in mice and in vitro.
Photys TherapeuticsNovo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront.